| References |
1. Hanauske AR, Wüster KC, Lehmer A, Rotter M, Schneider P, Kaeser-Fröhlich A, Rastetter J, Depenbrock H. Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro. Eur J Cancer. 1995 Sep;31A(10):1677-81. PubMed PMID: 7488424. 2. Hüttmann A, Mross K, Hossfeld DK. Determination of the new podophyllotoxin derivative NK 611 in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 1993 Oct 29;620(2):233-8. PubMed PMID: 8300791. 3. Mross K, Hüttmann A, Herbst K, Hanauske AR, Schilling T, Manegold C, Burk K, Hossfeld DK. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Cancer Chemother Pharmacol. 1996;38(3):217-24. PubMed PMID: 8646795. 4. Daley L, Guminski Y, Demerseman P, Kruczynski A, Etiévant C, Imbert T, Hill BT, Monneret C. Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide, and NK 611. J Med Chem. 1998 Nov 5;41(23):4475-85. PubMed PMID: 9804687. |
